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Background: The thoracic or thoracoabdominal aortic aneurysm surgery may cause spinal cord ischemia because
of aortic cross-clamping and may result in severe postoperative complications caused by spinal cord injury.
Ischemia/reperfusion injury may directly or indirectly be responsible for these complications. In this study we
sought to determine whether combination of iloprost and montelukast can reduce the ischemia/reperfusion injury
of spinal cord in a rat model.
Methods: Medulla spinalis tissue concentrations of interleukin-6 (IL-6), myeloperoxidase (MPO) and heat shock
protein 70 (HSP-70) were determined in 3 groups of Spraque Dawley rats: control group (operation with cross
clamping and intraperitoneal administration of 0.9% saline, n = 7), sham group (operation without cross clamping,
n = 7), and study group (operation with cross-clamping and intraperitoneal administration of iloprost (25 ng/kg) and
montelukast (1 mg/kg), n = 7). The abdominal aorta was clamped for 45 minutes, with a proximal (just below the
left renal artery) and a distal (just above the aortic bifurcation) clip in control and study groups. Hindlimb motor
functions were evaluated at 6, 12, 24, and 48 hours using the Motor Deficit Index score. All rats were sacrificed
48 hours after the procedure and spinal cord tissue levels of myeloperoxidase, interleukin-6, and heat shock protein
(HSP-70) were evaluated as markers of oxidative stress and inflammation. Histopathological analyses of spinal cord
were also performed.
Results: The tissue level of HSP-70 was found to be similar among the 3 groups, however, MPO was highest and
IL-6 receptor level was lowest in the control group (p = 0.007 and p = 0.005; respectively). In histopathological
examination, there was no significant difference among the groups with respect to the neuronal cell degeneration,
edema, or inflammation, but vascular congestion was found to be significantly more prominent in the control
group than in the sham or in the study group (p = 0.05). Motor deficit index scores at 24 and 48 hours after
ischemia were significantly lower in the study group than in the control group.
Conclusion: This study suggests that combined use of iloprost and montelukast may reduce ischemic damage in
transient spinal cord ischemia and may provide better neurological outcome.* Correspondence: drselcukg@hotmail.com
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The thoracic or thoracoabdominal aortic aneurysm surgery
may cause spinal cord ischemia because of aortic cross-
clamping, and so severe postoperative complications may
develop such as paraplegia [1,2]. The incidence of paraple-
gia has been reported to be as high as 35% in some series
[3]. Several strategies have been applied for preventing
paraplegia due to spinal cord ischemia and have included
the use of shunts, systemic hypothermia, spinal fluid drain-
age, and ischemic preconditioning [4,5].
Previous studies showed that release of oxygen free
radicals by macrophages and neutrophils are associated
with ischemia/reperfusion injury (IRI) and free radical
generation, lipid peroxidation or influx of calcium into
cells can cause neuronal cell death in the spinal cord
[6-8]. Cytokines such as interleukin-6 (IL-6) are important
mediators of inflammatory response in ischemia. [9].
Myeloperoxydase (MPO) is one of the distinct indicators
for the tissue infiltration of neutrophilic granulocytes and
increased MPO activity as a response to the IRI is reported
in the end organ tissue [10]. On the contrary, the cellular
stress response can mediate cellular protection through
expression of heat shock protein (HSP-70), which can
interfere with the process of apoptotic cell death [11].
In literature some antioxidative and antiinflammatory
agents like simvastatin [12], or N-acetylcysteine [13] are
used to prevent paraplegia due to aortic ischemia in ani-
mal models. Iloprost, a stable prostacyclin analog that
contributes to inhibition of platelet aggregation, vaso-
dilatation and cytoprotection, has been considered as a
neuronal cell saver and used in some experimental stud-
ies [14,15]. Montelukast, is a selective cysteinyl leukotriene
(CysLT1) receptor antagonist. Since cysteinyl leukotrienes
including LTC4, LTD4 and LTE4 are potent inflammatory
mediators involved in the central nervous diseases such as
ischemia [17], montelukast is used for the prevention of
IRI in animal studies [16,17]. In this study we sought to de-
termine whether combination of iloprost and montelukast
can reduce the IRI of spinal cord in a rat model.
Methods
Animal preparation
This study was approved by the Animal Experimental
Committee of Duzce University Graduate School of Medi-
cine Animal care and all procedures were performed
according to the guide for the care and use of laboratory
animals by the National Institutes of Health.
A total of 21 male Spraque-Dawley rats weighed be-
tween 250 and 350 gr were used for the experiment. None
of them had any neurological disorders before operation.
Study groups
Twenty one rats were randomly allocated into 3 groups.
In the sham group (n = 7) laparatomy was performed inthe same way but without aortic occlusion. In the control
group (n = 7), after laparotomy, abdominal aorta was
clamped for 45 minutes with a proximal (just below the left
renal artery) and a distal (just above the aortic bifurcation)
clip. In the study group (n = 7) iloprost (25 ng/kg) and
montelukast (1 mg/kg) were administered intraperitoneally
for 30 minutes before and during the same clamping
procedure as in control group. 400 IU/kg of heparin was
administered intraperitoneally to all animals immediately
before the procedure. All cross-clamped groups were re-
perfused after spinal cord ischemia of 45 minutes.
Montelukast sodium parenteral preparation method:
We did not have commercial parenteral form of mon-
telukast. For this reason parenteral form was prepared
from oral tablets. Ten tablets of montelukast 10 mg
(OnceairW Merck & Co. Inc., Whitehouse Station, NJ,
USA) was dissolved in 10 milliliters of ethanol. The
solution was centrifuged for 5 minutes at 5000 rpm,
ethanol-insoluble excipients were precipitated and the
supernatant was taken. Obtained supernatant was fil-
tered in 0.2 mM filter. The resulting solution was concen-
trated with evaporation method and reduced to a volume
of 3 ml. In this solution, there was approximately 30 mg/
mL concentration of montelukast sodium. 100 mL of this
solution is injected into the high-performance liquid chro-
matography (HPLC) system semipreparative each time
and were fractioned according to time of extracting from
chromatogram.
Method which has been previously validated in HPLC
device is as follows: TSP HPLC device was used [18]. Mo-
bile phase was water-acetonitrile (5:95 vv) of 3 mL/min
rate was used. Filled with C18 10x250 mm (5 mm particle
diameter) RP Semipreparative (ACE) column was used.
Measurings have done with 225 nm wavelength UV de-
tector. Solutions HPLC grade were used.
Peak of montelukast sodium was at 12.115 minutes in
HPLC chromatogram. Fraction was began to gather at the
beginning of the peak and terminated at the end of peak.
Same process was repeated until amount of montelukast
sodium reached the desired level in the obtained fraction
(approximately 20 again), and fractions were collected
together.
The amount of drug obtained from the fraction was
measured by analytical HPLC. Commercial preparation of
Onceair was used as the standard for measuring. 1 tablet
dissolved in 10 ml of ethanol and stock solution was
obtained. Three different calibration standards established
by dilution of this solution. Calibration curve was created
by the ratio of the peak areas of montelukast sodium.
5 mL was injected into the fraction obtained from the
analytical system. In this method, 1 mL/min rapid water-
acetonitrile (5:95 vv) was used as the mobile phase.
4.6 × 250 mm C18 filled (5 mm particle diameter) RP
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length of 225 nm was measured.
As a result of this analysis, the purity and concentration
of montelukast sodium which obtained with fraction were
measured. The amount of montelukast sodium was deter-
mined by placing the peak area of obtained fraction in
HPLC into calibration curve (Figure 1). Liquid phase in
fraction evaporated. The remaining balance substantially
diluted with distilled water to provide 10 mg/mL concen-
tration. Purity ratio was found as 97.874%, respectively
(Figure 2).
The obtained pure montelukast sodium solution was fil-
tered with 0.2 mm membrane filter to provide sterilization,
and injected rats as 1 mg/kg intraperitoneal dose (0.1 mL
per kg, 0.025 mL injection, for example 250 g rat).Operative Procedure and Technique
Rats were premedicated with ketamine (50 mg/kg) and
xylazine (5 mg/kg) intraperitoneally. The maintenance of
anesthesia was established with intermittent delivery of
ketamine, without endotracheal intubation and mechanical
ventilation. Intraperitoneal cephalosporine (10 mg/kg) was
administered before skin incision. Postoperative analgesia
was provided with tramadol per 12 hours. Temperature
probe was inserted into the rectum.
After the surface cleaning of the surgical area and stand-
ard midline laparatomy, the abdominal aorta was explored
trough a transperitoneal approach retracting the intes-
tines. The spinal cord ischemia was induced by clamping
the aorta with mini aneurysm clamp between just below
the left renal artery and just proximal to the aortic bifur-
cation. Temperature was maintained between 36.5 and
37.5°C during the spinal procedure with heating lamp. At
the end of surgery anterior abdominal wall was sutured by
using 5/0 polypropylene suture in all rats.
At 48th hour all animals were anesthetized with
penthobarbital (20 mmg/kg) and sacrificed. The spinal
cord tissue was extracted and fixed in buffered formalinFigure 1 Pure montelukast sodium obtained with preparative HPLC cfor 7 days to analyze the tissue level of HSP-70, IL-6
and MPO and histopathological examination.Neurological Assessment
After reperfusion, two of the study authors who are
blinded to the groups of the animals have evaluated the
hindlimb motor function at 6, 12, 24, and 48 hours using
the Motor Deficit Index (MDI) score, which was measured
by ambulation and placing/stepping responses [19]. Walk-
ing with lower extremities was graded as follows: 0 nor-
mal, (symmetrical and coordinated ambulation); 1 toes flat
under body when walking, but ataxia present; 2 knuckle
walking; 3 unable to knuckle walk but some movement of
the hindlimbs; and 4 no movement or drags lower extrem-
ities. A motor deficit index was calculated for each rat at
each time interval.
For evaluation of sensory function, the placing/stepping
reflex was assessed based on the dragging movements and
responses of the hindpaw dorsum. A coordinating lifting,
placing and stepping responses were observed when touch-
ing the hindpaw. Then, sensorial function was graded as
follows: 0 normal; 1 some response present (weak); and 2
no response to pinch.
The maximal MDI score was 6 (score of 4 for ambula-
tion and 2 for the placing/stepping reflex).Histopathological Assessment
In all animals after midline laparotomy spinal cord tissue
was removed and fixed in 10% formalin for histopatho-
logical examination. Paraffin sections (4 μm thickness) were
prepared. 5 μm thick sections were placed on polylysine-
coated slides and stained with hematoxylin and eosin
(H & E). The slides were evaluated under light microscopy
(Olympus BX51; Olympus Corp., Tokyo, Japan) at 200 ×
magnification in terms of neuronal cell degeneration,
edema, vascular congestion and inflammation. Histopatho-
logical assessment was performed by a study author, who is
blinded to the groups of the animals.hromatogram device.
Figure 2 Purity ratio of montelukast sodium in HPLC.
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Analysis of HSP
Paraffin sections (4 μm thick) were prepared. Tissue sec-
tions were deparaffinized and hydrated in xylenes and
graded alcohol. The sections were incubated with primary
anti-HSP70 (clone BRM.22, dilution 1/80, Biogenex, San
Ramon, California) diluted in buffer. Phosphate-buffered
saline (PBS) was used as negative control.
Analysis of IL-6
The polyclonal anti-human IL-6 receptor antibody C-20
(Santa Cruz Biotechnologies, Santa Cruz, CA, USA) was
used for the immunohistochemical detection of IL-6
receptor. This antibody was diluted 1:20. IL-6 receptor
immunostaining was also performed according to a
streptavidin-biotin-peroxidase protocol. The secondary
anti-rabbit antibody was diluted 1:500. Negative con-
trols were performed by omitting the first antibody.
Analysis of MPO
The spinal cord tissue MPO activity was evaluated
immuno-histochemically using an anti-MPO kit according
to the manufacturer’s protocol. Briefly, samples on
polylysine-coated slides were deparaffinized and rehy-
drated. Then, the microwave antigen retrieval procedure
was performed, and the samples were incubated in a 3%Table 1 Immunohistochemical results of the medulla spinalis
Grade Control group Sham
Number % Numb
MPO 0 2 28.6 7
1 5 71.4 0
HSP 0 2 28.6 4
1 4 57.1 3
2 1 14.3 0
IL-6 0 0 0 5
1 7 100 2
2 0 0 0H2O2 solution to inhibit endogenous peroxidase. To
block nonspecific background staining, the sections
were incubated with a blocking solution. Then, the sec-
tions were incubated with primary anti-MPO antibody,
followed by incubation with biotinylated goat anti-
mouse antibody. After incubating with the chromogenic
substrate (DAB), the sections were counterstained with
H & E.
The slides were examined under a light microscope.
The staining of cytoplasmic MPO in the neutrophils was
evaluated, and the results were expressed as the percent-
age of neutrophils cytoplasmically stained positive for
MPO.
Tissues with no evidence of staining, or only rare
scattered positive cells, less than 3%, were recorded as
negative. The immunohistochemical results were evalu-
ated for intensity and frequency of staining. The inten-
sity of staining was graded as 0 (negative), 1 (weak), 2
(moderate), and 3 (strong). The frequency was graded
from 0 to 4 by the percentage of positive cells as follows:
grade 0, <3%; grade 1, 3-25%; grade 2, 25-50%; grade 3,
50-75%; grade 4, more than 75%. The index score was
the product of multiplication of the intensity and fre-
quency grades, which was then classified into a 4 point
scale: index score 0 = product of 0, index score 1 = prod-
ucts 1 and 2, index score 2 = products 3 and 4, index
score 3 = products 6 through 12.tissue
group Study group P value
er % Number %
100 5 71.4 0.007
0 2 28.6
57.1 5 71.4 0.373
42.9 2 28.6
0 0 0
71.4 4 57.1 0.005
28.6 3 42.9
0 0 0
Table 2 Histopathologic results of the medulla spinalis tissue
H&E Grade Control group Sham group Study group P value
Number % Number % Number %
Edema 0 0 0 4 57.1 3 42.9 0.06
1 6 85.7 3 42.9 4 57.1
2 1 14.3 0 0 0 0
Cell Degeneration 0 1 14.3 4 57.1 3 42.9 0.289
1 5 71.4 2 28.6 4 57.1
2 1 14.3 1 14.3 0 0
Inflammation 0 3 42.9 4 57.1 4 57.1 0.304
1 0 0 0 0 0 0
2 2 28.6 3 42.9 3 42.9
3 2 28.6 0 0 0 0
Congestion 0 1 14.3 5 71.4 4 57.1 0.05
1 6 85.7 2 28.6 3 42.9
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Statistical analysis and calculations were performed by
using SPSS 15 for Windows (Chicago,IL). Results were
expressed as the mean (standard error mean). Kruskal-
Wallis analysis of variance was used to detect differences
among groups and statistical comparisons were made
using the Mann–Whitney U test. A p value of ≤ .05 was
considered statistically significant.Results
There was no statistically significant difference among the
groups with respect to the body temperature. The tissue
level of HSP-70 was found to be similar among the 3
groups, however, MPO and IL-6 receptor levels were lowest
in the study group (p = 0.007 and p = 0.005; respectively)
(Table 1).Figure 3 Hematoxylin and Eosin x200 staining of the medulla
spinalis tissue.In histopathologic examination, there was no signifi-
cant difference among the groups with respect to the
neuronal cell degeneration, edema, or inflammation, but
vascular congestion was found to be significantly more
prominent in the control group than in the sham or in
the study group (p = 0.05) (Table 2 and Figure 3).
Ischemic injury assessed by MDI score of hindlimb
was shown in Figure 4. Motor deficit index scores at 24
and 48 hours after ischemia were significantly lower in
the study group than in the control group.
Discussion
This study proposes that prophylactic administration of
iloprost-montelukast combination can reduce ischemia-Figure 4 Motor Deficit Index (MDI) assessed at 6 to 48 hours
after spinal cord ischemia. Each symbol represents the MDI score
of each rat.
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model of rats. Paraplegia is an uncommon but devastating
complication, which appears after thoracic or thoraco-
abdominal aortic surgery due to low perfusion pressure in
spite of various surgical and pharmacological interven-
tions [20,21]. The reported incidence of paraplegia ranges
from 3.8% to 17.6% [22].
Arterial vascularization of the spinal cord is similar in
rat and man, with a heterosegmental aorta and few anter-
ior radicular arteries reaching the anterior spinal artery
[23]. In addition, a rat model provides important advan-
tage for animal studies such as maintenance of normo-
thermia throughout the operation and the development of
prominent paraplegia after procedure [24]. So, many stu-
dies have been designed to detect the protective effects of
different pharmacological agents during ischemia of the
spinal cord in rat models as in our study.
In a previous study, Smith et al. [25] accounted for
mechanism of the spinal cord IRI. They have evaluated
inflammatory chemokine concentrations (interleukin-1β,
IL-6, keratinocyte-derived cytokine, macrophage inflam-
matory protein-α, monocyte chemotactic protein-1 and
TNF-α), which increased and peaked at 6 hours and 36
to 48 hours after reperfusion and they have suggested
that IRI of spinal cord includes 2 phases: ischemic attack
and subsequent inflammatory enhancement of the in-
jury. Since inflammation plays a key role in spinal cord
IRI, we analyzed spinal cord tissue level of IL-6 receptor,
HSP70 and MPO activity to evaluate the role of iloprost-
montelukast combination on the prevention of IRI. De-
creased MPO activity in the study group suggests that
this combination might be protective against spinal cord
injury via decreased neutrophil-mediated inflammation.
In literature there are several studies that evaluating
the protective effects of the different pharmacological
agents and their combination (simvastatin, pentoxifylline,
ilioprost and N-acetylcysteine combination, etc.) on the
spinal cord IRI [12,26]. In addition to other pharmaco-
logical effects, both iloprost and montelukast are shown to
be neuroprotective against IRI [16,27-29]. Montelukast,
which is a CysLT1 receptor antagonist, has a dose and
time dependent neuroprotective effect against IRI in a
mice model and its recommended effective doses are 0.1-
1.0 mg/kg, a therapeutic window of 30 minutes even when
administrated 30 min after ischemia [16,30]. Previously,
Ersahin et al. [31] showed that in a rat model of spinal
cord injury montelukast has neuroprotective and anti-
apoptotic effects on the spinal cord and it also ameliorates
bladder tissue damage. They suggest that these effects are
mediated by the inhibition of lipid peroxidation, neutro-
phil accumulation, and pro-inflammatory cytokine release.
In another experimental study Genovese et al. [32] also
showed that montelukast can reduce the spinal cord
inflammation and tissue injury, neutrophil infiltration,TNF-α, COX-2 and pERK1/2 expression, PGE2 and LTB4
production, and apoptosis. In the present study, we sought
to explore the possible additive or synergistic effect of
iloprost and montelukast combination on the prevention
of IRI and we found that both histopathological findings
and clinical scores favor prophylactic use of these combi-
nations in this rat model of spinal cord injury. Since two
important inflammatory markers, MPO and IL-6 recep-
tors, were found to be lower in the study group than in
the control group, we propose that anti-inflammatory ef-
fects of this drug combination may reduce ischemic dam-
age to the spinal cord. Absence of difference among 3
groups with respect to the HSP-70 level suggests that anti-
apoptotic effect of this combination as a cell protective
mechanism could not be concluded from this study.
Main limitation of the present study is preparation of
the parenteral form of montelukast from oral tablets due
to the absence of commercial parenteral form of this
drug in our country.
Conclusions
This study suggests that in rat model of spinal cord
injury prophylactic use of iloprost-montelukast com-
bination may reduce ischemic damage of spinal cord
via anti-inflammatory effects and may provide better
neurological outcome. Efficacy of different dosage stra-
tegies and different administration durations of these
drugs should be evaluated in further studies.
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